Drug: Remodelin - Cancerrxgene - Genomics of Drug Sensitivity in Cancer

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project

at the Wellcome Sanger Institute

(UK) and the Center for Molecular Therapeutics

, Massachusetts General Hospital Cancer Center

(USA). This work is funded by Wellcome

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).

https://www.cancerrxgene.org/compound/Remodelin/2057/scatter/CDKN2A_mut?tissue=PANCANCER&screening_set=GDSC2

Genomics of Drug Sensitivity in Cancer

Compound: Remodelin

Drug Target:

Drug Target pathway: Unclassified

DatasetDatasets
GDSC1: Screened in 96 or 384-well plates with Cyto60 or Resazurin endpoint
GDSC2 (recommended where available): 1536-well plates with CellTiterGlo endpoint
See documentation for more information and screening differences

Tissue specific analysis

Remodelin IC50 values for CDKN2A_mut